Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization

BACKGROUND: Despite the success of HER2-targeted therapy in achieving prolonged survival in approximately 50% of treated individuals, treatment resistance is still an important challenge for HER2+ breast cancer (BC) patients. The influence of both adaptive and innate immune responses on the therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qi, Xiu, Bingqiu, Zhang, Liyi, Chen, Ming, Chi, Weiru, Li, Lun, Guo, Rong, Xue, Jingyan, Yang, Benlong, Huang, Xiaoyan, Shao, Zhi-Ming, Huang, Shenglin, Chi, Yayun, Wu, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577936/
https://www.ncbi.nlm.nih.gov/pubmed/36252997
http://dx.doi.org/10.1136/jitc-2022-004666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577936/
https://www.ncbi.nlm.nih.gov/pubmed/36252997
http://dx.doi.org/10.1136/jitc-2022-004666

Ejemplares similares